Blizard Institute and the National Centre for Bowel Research, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Pharmacol Res Perspect. 2022 Apr;10(2):e00900. doi: 10.1002/prp2.900.
The gastrointestinal (GI) hormone motilin helps control human stomach movements during hunger and promotes hunger. Although widely present among mammals, it is generally accepted that in rodents the genes for motilin and/or its receptor have undergone pseudonymization, so exogenous motilin cannot function. However, several publications describe functions of low concentrations of motilin, usually within the GI tract and CNS of mice, rats, and guinea pigs. These animals were from institute-held stocks, simply described with stock names (e.g., "Sprague-Dawley") or were inbred strains. It is speculated that variation in source/type of animal introduces genetic variations to promote motilin-sensitive pathways. Perhaps, in some populations, motilin receptors exist, or a different functionally-active receptor has a good affinity for motilin (indicating evolutionary pressures to retain motilin functions). The ghrelin receptor has the closest sequence homology, yet in non-rodents the receptors have a poor affinity for each other's cognate ligand. In rodents, ghrelin may substitute for certain GI functions of motilin, but no good evidence suggests rodent ghrelin receptors are highly responsive to motilin. It remains unknown if motilin has functional relationships with additional bioactive molecules formed from the ghrelin and motilin genes, or if a 5-TM motilin receptor has influence in rodents (e.g., to dimerize with GPCRs and create different pharmacological profiles). Is the absence/presence of responses to motilin in rodents' characteristic for systems undergoing gene pseudonymization? What are the consequences of rodent supplier-dependent variations in motilin sensitivity (or other ligands for receptors undergoing pseudonymization) on gross physiological functions? These are important questions for understanding animal variation.
胃肠道激素胃动素有助于控制饥饿时人体胃部的运动并促进饥饿感。虽然胃动素广泛存在于哺乳动物中,但人们普遍认为,在啮齿动物中,胃动素及其受体的基因已经经历了伪命名化,因此外源性胃动素不能发挥作用。然而,有几个出版物描述了低浓度胃动素的功能,通常在小鼠、大鼠和豚鼠的胃肠道和中枢神经系统内。这些动物来自研究所持有的品系,仅用品系名称(例如“Sprague-Dawley”)简单描述,或为近交系。有人推测,动物来源/类型的差异会引入遗传变异,从而促进胃动素敏感途径。也许,在某些人群中,胃动素受体存在,或者具有良好亲和力的不同功能活性受体对胃动素具有亲和力(表明保留胃动素功能的进化压力)。生长激素释放肽受体具有最接近的序列同源性,但在非啮齿动物中,这些受体彼此的配体亲和力较差。在啮齿动物中,生长激素释放肽可能替代胃动素的某些胃肠道功能,但没有很好的证据表明啮齿动物生长激素释放肽受体对胃动素高度敏感。目前尚不清楚胃动素是否与生长激素释放肽和胃动素基因形成的其他生物活性分子具有功能关系,或者 5-TM 胃动素受体是否对啮齿动物有影响(例如,与 GPCR 二聚化并产生不同的药理学特征)。在啮齿动物中缺乏/对胃动素的反应是否是基因伪命名化系统的特征?在对胃动素敏感性(或经历伪命名化的其他受体的配体)存在供应商依赖性变化的情况下,对大体生理功能有何影响?这些对于理解动物变异是重要的问题。